![]() |
市場調查報告書
商品編碼
1496757
藥物發現市場:按藥物類型、技術、治療領域和最終用戶分類 - 2024-2030 年全球預測Drug Discovery Market by Drug Type (Biologic Drugs, Small Molecule Drugs), Technology (Bioanalytical Instruments, Biochips, Bioinformatics), Therapeutic Area, End User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年藥物發現市場規模為623.8億美元,2024年將達711.2億美元,預計2030年將達到1571.3億美元,複合年成長率為14.10%。
藥物發現是一個多方面且複雜的過程,涉及識別新化合物、闡明生物標的以及確定疾病的治療潛力。這個過程是開發新藥的基礎,需要生物學、化學、藥理學和醫學等各領域的科學家的合作。製藥和生物製藥行業研發(R&D)支出的增加以及政府對新興市場發展的支持正在推動市場成長。此外,管理臨床前研究期間產生的大量資料的需求不斷成長也推動了市場的成長。藥物發現和市場開拓需要巨額資金,而在藥物發現中使用動物的嚴格規範阻礙了市場成長。藥物發現領域的技術進步和創新,以及擴大使用人工智慧雲來創建簡化和自動化的藥物發現方法,預計將使藥物發現有望顯著成長。
主要市場統計 | |
---|---|
基準年[2023] | 623.8億美元 |
預測年份 [2024] | 711.2億美元 |
預測年份 [2030] | 1571.3億美元 |
複合年成長率(%) | 14.10% |
區域洞察
美洲擁有強大的藥物發現基礎設施,包括對研發的大量投資、大型製藥公司的存在以及完善的法規環境。醫療保健基礎設施投資的增加以及應對當地健康挑戰的醫療創新需求不斷成長,正在加速美洲對藥物發現解決方案的需求。在歐洲,先進的醫療保健系統、大量的政府和私人資金以及對國家間創新與合作的高度重視正在推動藥物發現的需求。在中東和非洲,由於醫療支出的增加和當地製藥業發展的努力,需求正在增加。由於人口眾多、經濟日益繁榮、醫療基礎設施改善、醫療意識不斷增強,以及政府支持生物技術和製藥行業的舉措不斷湧現,亞太地區正迅速成為藥物發現市場的主要參與者。
FPNV定位矩陣
FPNV定位矩陣對於評估藥物發現市場供應商的市場定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對藥物發現市場中供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在藥物發現市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[189 Pages Report] The Drug Discovery Market size was estimated at USD 62.38 billion in 2023 and expected to reach USD 71.12 billion in 2024, at a CAGR 14.10% to reach USD 157.13 billion by 2030.
Drug discovery is a multifaceted and intricate process that encompasses the identification of novel compounds, the elucidation of their biological targets, and the determination of their therapeutic potential for the treatment of diseases. This process is fundamental to developing new medicines and involves a collaborative effort among scientists from various disciplines, including biology, chemistry, pharmacology, and medicine. Rising research and development (R&D) expenditure in the pharmaceutical and biopharmaceutical industry and favorable government support for developing drug discovery platforms are propelling the market growth. In addition, the increasing need to manage large amounts of data generated during preclinical studies is fueling market growth. The necessity of extensive capital for drug discovery and development and stringent norms for animal usage in drug discovery are hampering market growth. Technological advancements and innovations in drug discovery and the growing use of AI cloud to create a streamlined and automated approach to drug discovery are expected to be poised for significant growth in drug discovery.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 62.38 billion |
Estimated Year [2024] | USD 71.12 billion |
Forecast Year [2030] | USD 157.13 billion |
CAGR (%) | 14.10% |
Regional Insights
Americas represents a robust drug discovery infrastructure with significant investments in R&D, a strong presence of pharmaceutical giants, and a conducive regulatory environment. Increasing investment in healthcare infrastructure and growing need for medical innovation to address local health concerns are accelerating the need for drug discovery solutions in the Americas. In Europe, the need for drug discovery is fueled by advanced healthcare systems, substantial government and private funding, and a strong focus on innovation and collaboration across countries. The Middle East and Africa exhibit growing need, with increased healthcare spending and initiatives to foster local pharmaceutical industries. The Asia-Pacific region is rapidly emerging as a significant player in the drug discovery market due to its large population, increasing economic prosperity, improvements in healthcare infrastructure, rising healthcare awareness, and government initiatives to support the biotechnology and pharmaceutical sectors.
Market Insights
The market dynamics represent an ever-changing landscape of the Drug Discovery Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Drug Discovery Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Drug Discovery Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Evommune and Accutar Biotechnology Announce AI Drug Discovery Collaboration
Evommune, Inc. collaborated with Accutar Biotechnology, Inc., specializing in AI-driven drug discovery, to co-develop therapies for debilitating dermatological conditions. This strategic collaboration intends to leverage Accutar's AI platform to accelerate Evommune's drug discovery and development process, circumventing traditional bottlenecks and paving the way for innovative treatments. [Published On: 2023-11-28]
IGC Pharma signs agreement to adopt AI solutions into drug discovery
IGC Pharma signed an agreement with the University of Los Andes in Colombia to develop and adopt generative artificial intelligence (AI) solutions to detect, develop, and trial new drugs. Under the agreement, the company leverages generative AI to streamline the efficiency of its clinical trials, improve early Alzheimer's disease detection approaches, and enhance drug interaction assessments. [Published On: 2023-11-22]
University of Tsukuba and Astellas Confirm a Strategic Partnership
Astellas Pharma Inc. partnered with the University of Tsukuba to integrate "targeted protein degradation" technology into their portfolio, a pivotal step that enhances their research capabilities. The implementation of this innovative approach aims to transcend the limitations of traditional drug development by strategically degrading disease-causing proteins. [Published On: 2023-11-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Drug Discovery Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Alacrita Holdings Limited, Astex Pharmaceuticals by Otsuka Pharmaceutical Co., Ltd., Astrazeneca PLC, Atomwise, Inc., BenevolentAI, Bio-Rad Laboratories, Inc., BioSymetrics Inc., Charles River Laboratories International, Inc., Chembridge Corporation, Cloud Pharmaceuticals, Inc., Dalriada Drug Discovery, Deciphera Pharmaceuticals, Inc., Evotec SE, F. Hoffmann-La Roche Ltd., GENFIT SA, Incyte Corporation, International Business Machines Corporation, Intra-Cellular Therapies Inc., Merck KGaA, Microsoft Corporation, NVIDIA Corporation, PerkinElmer, Inc., Pharmacelera SL, Piramal Group, Recursion Pharmaceuticals, Inc., Schrodinger, Inc., Shimadzu Corporation, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage